ESLA - NASDAQ

Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

ESLAยทNASDAQ

$1.17

+0.41%
HealthcareBiotechnology

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.34M
EPS-0.3500
P/E Ratio-3.34
Earnings Date06/03/2026
Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. Fair Value Envelope

ESLA ยท NASDAQ

Our analysis suggests that ESLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.1698, this represents a potential HIDDEN relative to our calculated worth for Estrella Immunopharma, Inc..

HIDDEN
Intrinsic Value
Current Price: $1.1698

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$624.5M
+ Cash & Equivalents$1.4M
Firm Value-$623.1M
- Debt$0
Equity Value-$623.1M
/ Shares Outstanding37,065,589B
DCF Value-$17
OVERVALUED BY 1537%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$3.2M
-$5.6M
-$9.8M
-$17.4M
-$30.7M
-$54.2M
-$95.8M
-$169.1M
-$298.7M
-$527.7M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$3.2M
-$5.6M
-$9.8M
-$17.4M
-$30.7M
-$54.2M
-$95.8M
-$169.1M
-$298.7M
-$527.7M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$2.9M
-$4.8M
-$7.8M
-$12.8M
-$20.9M
-$34.2M
-$55.9M
-$91.4M
-$149.4M
-$244.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ESLA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.